Jean-Marc Classe, Cecile Loaec, P Gimbergues, S Alran, C Tunon de Lara, P F Dupre, Roman Rouzier, C Faure, N Paillocher, M P Chauvet, G Houvenaeghel, M Gutowski, P De Blay, J L Verhaeghe, E Barranger, C Lefebvre, C Ngo, G Ferron, C Palpacuer, L Campion
PURPOSE: GANEA2 study was designed to assess accuracy and safety of sentinel lymph node (SLN) after neo-adjuvant chemotherapy (NAC) in breast cancer patients. METHODS: Early breast cancer patients treated with NAC were included. Before NAC, patients with cytologically proven node involvement were allocated into the pN1 group, other patient were allocated into the cN0 group. After NAC, pN1 group patients underwent SLN and axillary lymph node dissection (ALND); cN0 group patients underwent SLN and ALND only in case of mapping failure or SLN involvement...
October 20, 2018: Breast Cancer Research and Treatment